Moosa Mohammadi Lab  NYU Medical Center  MSB 425 / 431  
550  1st Ave,  New York,  NY 10016  
   (212)  263 - 7122  
    Home Publication Lecture Animation   People  
 
Home
Publication
Lecture
Animation
People
 

      Publication

  1. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol. 2008 Aug 11;182(3):459-65
  2. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J. Clin. Invest. 118(8): 2822-2831 (2008)
  3. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism. Volume 8, Issue 1, 2 July 2008, Pages 77-83
  4. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous β-catenin. Human Mutation, 2008 Mar;29(3):390-7
  5. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. doi:10.1172/JCI32409, 2007 Nov 8
  6. A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases. Molecular Cell, Vol 27, 717-730, 07 September 2007
  7. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117:2684-2691 (2007)
  8. Tissue-specific expression of beta KLOTHO and fibroblast growth factor receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem, 10.1074/jbc.M704165200
  9. Endocrine Regulation of the Fasting Response by PPARN1-Mediated Induction of Fibroblast Growth Factor 21. Cell Metabolism, Vol 5, 415-425, 06 June 2007
  10. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007 May 21
  11. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(18): 7432-7
  12. Impaired FGF signaling contributes to cleft lip and palate. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 4512
  13. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of FGF19 Subfamily Members. Mol. Cell. Biol. 2007; doi:10.1128/MCB.02249-06
  14. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007 January 18. doi: 10.1172/JCI29884
  15. Hedgehogs like it sweet, too. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 17069
  16. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. Journal of biological chemistry. 2006; 281:867
  17. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes & development. 2006; 20: 185
  18. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 6281
  19. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Molecular & cellular endocrinology. 2006; 254-255: 60
  20. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. Journal of biological chemistry. 2006; 281: 15694
  21. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Molecular & cellular biology. 2005; 25: 671
  22. Understanding the molecular basis of apert syndrome. Plastic & reconstructive surgery. 2005; 115: 264
  23. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Current opinion in structural biology. 2005; 15: 506
  24. Structural basis for fibroblast growth factor receptor activation. Cytokine & growth factor reviews. 2005; 16: 107
  25. Identification of phosphopeptides by MALDI Q-TOF mass spectrometry in positive and negative ion modes after methyl esterification. Molecular & cellular proteomics. 2005; 4: 809
  26. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology. 2005; 146: 4647
  27. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Human molecular genetics. 2004; 13: 2313
  28. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry. 2004; 43: 4724
  29. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Human molecular genetics. 2004; 13: 69
  30. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 935
  31. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. Journal of biological chemistry. 2003; 278: 34226
  32. Structure-based mutational analyses in FGF7 identify new residues involved in specific interaction with FGFR2IIIb. FEBS letters. 2003; 552: 150
  33. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 2266
  34. Synthesis of sulfosucrose derivatives for evaluation as regulators of fibroblast growth factor activity. Tetrahedron letters. 2002; 43: 8047
  35. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Molecular & cellular biology. 2002; 22: 7184
  36. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Molecular & cellular biology. 2001; 21: 5946
  37. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 7182
  38. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. Journal of biological chemistry. 2001; 276: 4322
  39. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer research. 2000; 60: 4152
  40. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 2000; 101: 413
  41. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Molecular cell. 2000; 6: 743
  42. Structural basis for FGF receptor dimerization and activation. Cell. 1999; 98: 641
  43. Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Molecular biology of the cell. 1999; 10: 23-33
  44. Autoregulatory mechanisms in protein-tyrosine kinases. Journal of biological chemistry. 1998; 273: 11987
  45. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO journal. 1998; 17: 5896
  46. Differential pre- and postsynaptic modulation of chemical transmission in the squid giant synapse by tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 1990
  47. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997; 276: 955
  48. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Molecular & cellular biology. 1996; 16: 977
  49. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 1996; 86: 577
  50. Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cgamma1. Journal of biological chemistry. 1996; 271: 31154
  51. Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. Journal of biological chemistry. 1995; 270: 5065
  52. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995; 373: 536-539
  53. Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO journal. 1995; 14: 4470
  54. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. Journal of biological chemistry. 1994; 269: 17056
  55. Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells. Journal of biological chemistry. 1994; 269: 14419
  56. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry. 1993; 32: 8742
  57. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science. 1993; 260: 1953
  58. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature. 1992; 358: 681
  59. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO journal. 1992; 11: 559
  60. Role of SH2-containing proteins in cellular signaling by receptor tyrosine kinases. Cold Spring Harbor symposia on quantitative biology. 1992; 57: 67
  61. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Molecular & cellular biology. 1991; 11: 5068
  62. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell. 1991; 65: 83
  63. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma. EMBO journal. 1990; 9: 4375
  64. Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity. Cell growth & differentiation. 1990; 1:191-200